Texas Oncology, Aetna Collaborate to Improve Patient Care Through Clinical Pathways
Texas Oncology and Aetna partnered to provide a practice-based program that reduced costs while maintaining adherence to treatment pathways and patient satisfaction in Medicare patients.
Prior Chemotherapy for Leukemia May Hinder Effective CAR T-Cell Development
Younger patients who received certain chemotherapies for solid tumors or leukemia may not have T cells capable of becoming effective CAR T-cells.
Precision Medicine Improves Survival in Late-Stage Cancer, Lowers Health Care Costs
Precision oncology strategies may improve overall survival for patients with refractory cancer while lowering the average per-week health care costs, resource utilization, and end-of-life costs.
Quality Initiatives, Health Care Reimbursement Crucial to APM Long-Term Success
A recent literature review analyzed the alternative payment models used in the real world and how they have affected the quality of oncology care.
Long-Term Follow-Up Shows BTK Inhibitor Produces Deep, Durable Responses in CLL
Treatment with a BTK inhibitor has been shown to yield good depth and duration of response in patients with chronic lymphocytic leukemia, regardless of TP53 status.
NCI Study Supports Screening for Heart Disease in Testicular Cancer Survivors
Results of a large study supported by the National Cancer Institute found that patients who survived testicular cancer are at a higher risk of developing heart disease.
Clinical Benefit, Limited Adverse Events From CAR-T Therapy for NHL
Long-term data show that a CAR-T therapy induces significant clinical benefit without added adverse events among patients with refractory aggressive non-Hodgkin lymphoma.
Medicare ACO Enrollment Improves Quality of Breast, Colorectal Cancer Screening
Widespread use of alternative payment models may improve the quality of breast and colorectal cancer screening programs.
